I am a
Home I AM A Search Login

Papers of the Week

Papers: 5 Sep 2020 - 11 Sep 2020

Human Studies, Pharmacology/Drug Development


2020 Sep 07

J Eur Acad Dermatol Venereol

A phase 2, open-label study of single dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy.


Paller AS, Siegfried EC, Simpson EL, Cork MJ, Lockshin B, Kosloski MP, Kamal MA, Davis JD, Sun X, Pirozzi G, Graham NMH, Gadkari A, Eckert L, Ruddy M, Bansal A
J Eur Acad Dermatol Venereol. 2020 Sep 07.
PMID: 32893393.


Dupilumab has demonstrated efficacy and acceptable safety in adults and children (aged 6-17 years) with moderate-to-severe atopic dermatitis (AD), but effective systemic therapy with a favorable risk-benefit profile in younger children remains a significant unmet need.